Prostate Cancer (Adenocarcinoma) Clinical Trials

38 recruiting

Prostate Cancer (Adenocarcinoma) Trials at a Glance

38 actively recruiting trials for prostate cancer (adenocarcinoma) are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 13 trials, with the heaviest enrollment activity in Boston, Fuzhou, and Myrtle Beach. Lead sponsors running prostate cancer (adenocarcinoma) studies include First Affiliated Hospital of Fujian Medical University, Affidea Nu-med Center of Oncological DIagnostics and Therapy, and AdventHealth.

Browse prostate cancer (adenocarcinoma) trials by phase

Treatments under study

About Prostate Cancer (Adenocarcinoma) Clinical Trials

Looking for clinical trials for Prostate Cancer (Adenocarcinoma)? There are currently 38 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Prostate Cancer (Adenocarcinoma) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Prostate Cancer (Adenocarcinoma) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 38 trials

Recruiting
Phase 2

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium126 enrolled2 locationsNCT06844383
Recruiting
Not Applicable

Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1

Prostate Cancer (Adenocarcinoma)
St Vincent's Hospital, Sydney24 enrolled1 locationNCT07552922
Recruiting

Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria

Prostate CancerProstate Cancer MetastaticProstate Cancer (Adenocarcinoma)+3 more
Société Algérienne de Formation et Recherche en Oncologie2,000 enrolled24 locationsNCT07484971
Recruiting
Phase 3

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Prostate Cancer (Adenocarcinoma)
Canadian Cancer Trials Group830 enrolled340 locationsNCT06592924
Recruiting
Phase 1

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited67 enrolled8 locationsNCT06801236
Recruiting

Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy

Prostate Cancer (Adenocarcinoma)Radical ProstatectomyProstate Cancer (Post Prostatectomy)+2 more
Lithuanian University of Health Sciences500 enrolled1 locationNCT07516886
Recruiting
Phase 2

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Prostate Cancer (Adenocarcinoma)Prostate Cancer Patients Treated by Radiotherapy
Candel Therapeutics, Inc.45 enrolled7 locationsNCT07332000
Recruiting
Phase 2Phase 3

PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer

Prostate Cancer (Adenocarcinoma)Stereotactic Body Radiation Therapy (SBRT)Localized Prostate Cancer+2 more
Affidea Nu-med Center of Oncological DIagnostics and Therapy1,200 enrolled1 locationNCT07426055
Recruiting
Phase 2

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Prostate CancerProstate CarcinomaProstate Neoplasm+12 more
Shehzad Basaria, M.D.60 enrolled1 locationNCT06957691
Recruiting
Phase 1Phase 2

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

Prostate Cancer (Adenocarcinoma)
The Methodist Hospital Research Institute29 enrolled1 locationNCT07182279
Recruiting
Phase 2

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Metastatic Prostate CancerProstate Cancer (Adenocarcinoma)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins58 enrolled1 locationNCT06616597
Recruiting
Not Applicable

PSMA PET for Surveillance After Focal Therapy

Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic DiseaseProstate Cancer (Diagnosis)
University of Chicago62 enrolled1 locationNCT07115914
Recruiting

ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0

Prostate CancerProstate Cancer (Adenocarcinoma)Prostate Cancer Non-Metastatic
University of Milano Bicocca58 enrolled1 locationNCT07407608
Recruiting
Not Applicable

Dyadic Co-learning Intervention for Patients With Prostate Cancer and Their Spouses

Prostate Cancer (Adenocarcinoma)
National Taipei University of Nursing and Health Sciences60 enrolled2 locationsNCT07196488
Recruiting

Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer (X-SMILE)

Prostate Cancer (Adenocarcinoma)Localized Prostate CarcinomaProstate Hyperplasia+1 more
University of Zurich75 enrolled3 locationsNCT06834152
Recruiting
Phase 1

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

Prostate Cancer SurgeryProstate Cancer (Adenocarcinoma)Prostate CA
AdventHealth30 enrolled1 locationNCT06631521
Recruiting
Not Applicable

Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions

Prostate Cancer (Adenocarcinoma)
The Netherlands Cancer Institute54 enrolled1 locationNCT07391982
Recruiting

LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.

Prostate Cancer (Adenocarcinoma)
Jules Bordet Institute110 enrolled1 locationNCT07370597
Recruiting
Phase 1Phase 2

The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer

Prostate Cancer (Adenocarcinoma)
First Affiliated Hospital of Fujian Medical University6 enrolled1 locationNCT07363382
Recruiting
Not Applicable

Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery

Prostate Cancer (Adenocarcinoma)
Martini-Klinik am UKE GmbH102 enrolled2 locationsNCT07129551